Wang Xiang, Ren Xinxin, Lin Xu, Li Qi, Zhang Yingqiong, Deng Jun, Chen Binxin, Ru Guoqing, Luo Ying, Lin Nengming
Department of Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China.
Department of Pathology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, China.
Asian J Pharm Sci. 2024 Aug;19(4):100939. doi: 10.1016/j.ajps.2024.100939. Epub 2024 Jun 26.
Ferroptosis is a nonapoptotic form of cell death characterized by iron dependence and lipid peroxidation. Ferroptosis is involved in a range of pathological processes, such as cancer. Many studies have confirmed that ferroptosis plays an essential role in inhibiting cancer cell proliferation. In addition, a series of small-molecule compounds have been developed, including erastin, RSL3, and FIN56, which can be used as ferroptosis inducers. The combination of ferroptosis inducers with anticancer drugs can produce a significant synergistic effect in cancer treatment, and patients treated with these combinations exhibit a better prognosis than patients receiving traditional therapy. Therefore, a thorough understanding of the roles of ferroptosis in cancer is of great significance for the treatment of cancer. This review mainly elaborates the molecular biological characteristics and mechanism of ferroptosis, summarizes the function of ferroptosis in cancer development and treatment,illustrates the application of ferroptosis in patient's prognosis prediction and drug discovery, and discusses the prospects of targeting ferroptosis.
铁死亡是一种非凋亡形式的细胞死亡，其特征为铁依赖性和脂质过氧化。铁死亡参与了一系列病理过程，如癌症。许多研究证实，铁死亡在抑制癌细胞增殖中起重要作用。此外，已经开发出一系列小分子化合物，包括埃拉斯汀、RSL3和FIN56，它们可用作铁死亡诱导剂。铁死亡诱导剂与抗癌药物联合使用可在癌症治疗中产生显著的协同效应，接受这些联合治疗的患者比接受传统治疗的患者预后更好。因此，深入了解铁死亡在癌症中的作用对癌症治疗具有重要意义。本文综述主要阐述了铁死亡的分子生物学特征和机制，总结了铁死亡在癌症发生发展和治疗中的作用，阐述了铁死亡在患者预后预测和药物发现中的应用，并探讨了靶向铁死亡的前景。
